Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05486182 | Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer(ESTROTIMP) | active not recruiting | Phase 4 | 153 | GE HealthcareINDUSTRY | 1 | Aug 14, 2025 | clinicaltrials |
| NCT05732064 | Dexmedetomidine-esketamine Combined Nasal Administration and Perioperative Sleep Quality | completed | Phase 4 | 180 | Peking University First HospitalOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT07093931 | Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer | not yet recruiting | Phase 4 | 468 | Shandong Cancer Hospital and InstituteOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT05333328 | OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk(INTERSTELLAR) | recruiting | Phase 4 | 418 | Gangnam Severance HospitalOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT01490892 | Quantitative Subharmonic Breast Imaging | completed | Phase 4 | 219 | Thomas Jefferson UniversityOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT06920810 | Viscum Album for TNBC on Adjuvant Pembrolizumab(TNBNOBA) | recruiting | Phase 4 | 40 | Ilsan Cha hospitalOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT04781959 | A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy | completed | Phase 4 | 233 | Ottawa Hospital Research InstituteOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT05465031 | Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM) | recruiting | Phase 4 | 600 | Silesian Centre for Heart DiseasesOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT04330040 | Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer(SOLI) | completed | Phase 4 | 202 | AstraZenecaINDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT06868017 | Randomized Controlled Clinical Study of Efficacy and Safety of Initumab Combined with Pyrrotinib and Chemotherapeutic Agents in Neoadjuvant Therapy for HER2-positive Breast Cancer with Different Treatment Cycles | not yet recruiting | Phase 4 | 208 | The First Hospital of Jilin UniversityOTHER | 0 | Mar 10, 2025 | clinicaltrials |
| NCT06497660 | Effect of Neoadjuvant Chemotherapy on Cardiac Function of Perioperative Patients With Breast Cancer and New Strategies for Anesthesia | unknown | Phase 4 | 496 | Fujian Medical University Union HospitalOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT06777537 | Neoadjuvant Chemotherapy with or Without Talniflumate for the Treatment of Breast Cancer | not yet recruiting | Phase 4 | 200 | Shandong UniversityOTHER | 0 | Jan 16, 2025 | clinicaltrials |
| NCT04657679 | Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts(LEANORA) | terminated | Phase 4 | 21 | Georgetown UniversityOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06252662 | Liposomal Bupivacaine Vs Bupivacaine with Dexmedetomidine in Erector Spinae Plane Blocks for Mastectomies | recruiting | Phase 4 | 200 | United States Naval Medical Center, PortsmouthFED | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06641544 | The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer(IFANS) | recruiting | Phase 4 | 200 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06613373 | An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast Cancer | not yet recruiting | Phase 4 | 30 | Jiangsu Famous Medical Technology Co., Ltd.INDUSTRY | 0 | Sep 25, 2024 | clinicaltrials |
| NCT06578299 | Inetetamab Combined With Paclitaxel With/Without Pertuzumab for Previously Treated HER2-positive Advanced Breast Cancer | not yet recruiting | Phase 4 | 100 | Fudan UniversityOTHER | 0 | Aug 29, 2024 | clinicaltrials |
| NCT04790305 | Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer | recruiting | Phase 4 | 1,072 | Fudan UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06428682 | Role of TXA in Patients Undergoing Breast Free Flap Reconstruction | unknown | Phase 4 | 100 | University of VirginiaOTHER | 1 | Jun 5, 2024 | clinicaltrials |
| NCT06406127 | Effect of Alpha Lipoic Acid on Chemotherapy Induced Neurological Changes in Breast Cancer Patients | unknown | Phase 4 | 92 | Ain Shams UniversityOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06300099 | Dexamethasone Versus Dexmedetomidine as Adjuncts to Serratus Anterior Plane Block | unknown | Phase 4 | 126 | Al-Azhar UniversityOTHER | 0 | Mar 12, 2024 | clinicaltrials |
| NCT04904653 | The Effectiveness of Hemopatch® in the Reduction of Post-surgical Serous Drainage | unknown | Phase 4 | 118 | Instituto de Investigación Hospital Universitario La PazOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT06217185 | The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC). | recruiting | Phase 4 | 100 | Hebei Medical University Fourth HospitalOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06245824 | Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial | not yet recruiting | Phase 4 | 51 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05949424 | OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults(OPTI-DOSE) | unknown | Phase 4 | 30 | University Medical Center GroningenOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT04625517 | Performance of Contrast-Enhanced Spectral Mammography to Assess Neoadjuvant Chemotherapy Response (CEDM) | terminated | Phase 4 | 6 | University of Texas Southwestern Medical CenterOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT05860907 | Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis | not yet recruiting | Phase 4 | 384 | Fudan UniversityOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT05843292 | Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer(NeoSTEP) | not yet recruiting | Phase 4 | 48 | Shanghai Jiao Tong University School of MedicineOTHER | 0 | Jun 6, 2023 | clinicaltrials |
| NCT05861635 | The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression | unknown | Phase 4 | 42 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT05841849 | Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer | not yet recruiting | Phase 4 | 1,028 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT05036005 | Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)(NeoON) | unknown | Phase 4 | 108 | Institut fuer FrauengesundheitOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05452213 | Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients(CAPTOR-BC) | recruiting | Phase 4 | 1,000 | Institut fuer FrauengesundheitOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05809024 | Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy | unknown | Phase 4 | 100 | Yongsheng WangOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT00128297 | Pamidronate Administration in Breast Cancer Patients With Bone Metastases | completed | Phase 4 | 152 | Spanish Breast Cancer Research GroupOTHER | 1 | Mar 28, 2023 | clinicaltrials |
| NCT01298193 | Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer. | completed | Phase 4 | 212 | Spanish Breast Cancer Research GroupOTHER | 1 | Mar 7, 2023 | clinicaltrials |
| NCT04248179 | The Ultrasound-guided Multiple-injection Costotransverse Block for Mastectomy and Primary Reconstructive Surgery. | completed | Phase 4 | 36 | Zealand University HospitalOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT01035099 | RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF | completed | Phase 4 | 41 | Weill Medical College of Cornell UniversityOTHER | 1 | Dec 13, 2022 | clinicaltrials |
| NCT02419742 | Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen | completed | Phase 4 | 110 | Hoffmann-La RocheINDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
| NCT03948568 | Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT)(REaCT-RETT) | completed | Phase 4 | 262 | Ottawa Hospital Research InstituteOTHER | 1 | Sep 30, 2022 | clinicaltrials |
| NCT02679755 | Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer | completed | Phase 4 | 252 | PfizerINDUSTRY | 2 | Jul 27, 2022 | clinicaltrials |
| NCT05420454 | A Study for the Neoadjuvant Treatment of Breast Cancer | recruiting | Phase 4 | 1,576 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT05420467 | A Study for the Adjuvant Treatment of Breast Cancer | recruiting | Phase 4 | 2,413 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT04074460 | Volatile Anaesthesia and Perioperative Outcomes Related to Cancer Feasibility Study(VAPOR-C) | completed | Phase 4 | 169 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Jun 9, 2022 | clinicaltrials |
| NCT05302336 | AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer | unknown | Phase 4 | 402 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05291910 | Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer | unknown | Phase 4 | 70 | Chinese Academy of Medical SciencesOTHER | 1 | Mar 23, 2022 | clinicaltrials |
| NCT04705883 | Vaginal Prasterone In Vaginal Atrophy In Breast Cancer Survivors(VIBRA) | completed | Phase 4 | 10 | Hospital Clinic of BarcelonaOTHER | 1 | Feb 22, 2022 | clinicaltrials |
| NCT05191914 | Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 Inhibitors | unknown | Phase 4 | 20 | Liaoning Cancer Hospital & InstituteOTHER | 0 | Jan 14, 2022 | clinicaltrials |
| NCT04929548 | Exploratory Study of Neoadjuvant Treatment of HER2-positive Breast Cancer With Py in Combination With HP | not yet recruiting | Phase 4 | 20 | Wuhan UniversityOTHER | 0 | Jan 5, 2022 | clinicaltrials |
| NCT05131841 | Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC | unknown | Phase 4 | 60 | Zhejiang Cancer HospitalOTHER | 1 | Nov 23, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Aug 14, 2025source: clinicaltrials